BioGaia AB (publ)

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, IPSEY has a market cap of 64.9B. Regarding current trading prices, BIOGY is priced at $11.00, while IPSEY trades at $49.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas IPSEY's P/E ratio is 31.46. In terms of profitability, BIOGY's ROE is +0.24%, compared to IPSEY's ROE of +0.10%. Regarding short-term risk, BIOGY is less volatile compared to IPSEY. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check IPSEY's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, MKKGY has a market cap of 55.7B. Regarding current trading prices, BIOGY is priced at $11.00, while MKKGY trades at $25.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas MKKGY's P/E ratio is 18.18. In terms of profitability, BIOGY's ROE is +0.24%, compared to MKKGY's ROE of +0.09%. Regarding short-term risk, BIOGY is less volatile compared to MKKGY. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check MKKGY's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, MKGAF has a market cap of 54.5B. Regarding current trading prices, BIOGY is priced at $11.00, while MKGAF trades at $132.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas MKGAF's P/E ratio is 17.82. In terms of profitability, BIOGY's ROE is +0.24%, compared to MKGAF's ROE of +0.09%. Regarding short-term risk, BIOGY is less volatile compared to MKGAF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check MKGAF's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, TKPHF has a market cap of 50.6B. Regarding current trading prices, BIOGY is priced at $11.00, while TKPHF trades at $32.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas TKPHF's P/E ratio is 72.77. In terms of profitability, BIOGY's ROE is +0.24%, compared to TKPHF's ROE of +0.02%. Regarding short-term risk, BIOGY and TKPHF have similar daily volatility (0.00).Check TKPHF's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, HLNCF has a market cap of 43B. Regarding current trading prices, BIOGY is priced at $11.00, while HLNCF trades at $4.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas HLNCF's P/E ratio is 19.36. In terms of profitability, BIOGY's ROE is +0.24%, compared to HLNCF's ROE of +0.06%. Regarding short-term risk, BIOGY is less volatile compared to HLNCF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check HLNCF's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, SDZNY has a market cap of 34.6B. Regarding current trading prices, BIOGY is priced at $11.00, while SDZNY trades at $80.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas SDZNY's P/E ratio is 38.23. In terms of profitability, BIOGY's ROE is +0.24%, compared to SDZNY's ROE of +0.08%. Regarding short-term risk, BIOGY is less volatile compared to SDZNY. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check SDZNY's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, TEVJF has a market cap of 34B. Regarding current trading prices, BIOGY is priced at $11.00, while TEVJF trades at $29.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas TEVJF's P/E ratio is 24.12. In terms of profitability, BIOGY's ROE is +0.24%, compared to TEVJF's ROE of +0.21%. Regarding short-term risk, BIOGY and TEVJF have similar daily volatility (0.00).Check TEVJF's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, TAIPY has a market cap of 18.1B. Regarding current trading prices, BIOGY is priced at $11.00, while TAIPY trades at $14.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas TAIPY's P/E ratio is 82.35. In terms of profitability, BIOGY's ROE is +0.24%, compared to TAIPY's ROE of +0.02%. Regarding short-term risk, BIOGY is less volatile compared to TAIPY. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check TAIPY's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, ESALY has a market cap of 17.6B. Regarding current trading prices, BIOGY is priced at $11.00, while ESALY trades at $61.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas ESALY's P/E ratio is 20.54. In terms of profitability, BIOGY's ROE is +0.24%, compared to ESALY's ROE of +0.06%. Regarding short-term risk, BIOGY is less volatile compared to ESALY. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check ESALY's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, SGIOY has a market cap of 16.8B. Regarding current trading prices, BIOGY is priced at $11.00, while SGIOY trades at $9.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas SGIOY's P/E ratio is 15.67. In terms of profitability, BIOGY's ROE is +0.24%, compared to SGIOY's ROE of +0.14%. Regarding short-term risk, BIOGY is less volatile compared to SGIOY. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check SGIOY's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, BIOVF has a market cap of 16.4B. Regarding current trading prices, BIOGY is priced at $11.00, while BIOVF trades at $47.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas BIOVF's P/E ratio is 169.11. In terms of profitability, BIOGY's ROE is +0.24%, compared to BIOVF's ROE of +0.02%. Regarding short-term risk, BIOGY and BIOVF have similar daily volatility (0.00).Check BIOVF's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, SGIOF has a market cap of 16.3B. Regarding current trading prices, BIOGY is priced at $11.00, while SGIOF trades at $19.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas SGIOF's P/E ratio is 15.16. In terms of profitability, BIOGY's ROE is +0.24%, compared to SGIOF's ROE of +0.14%. Regarding short-term risk, BIOGY is less volatile compared to SGIOF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check SGIOF's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, IPSEF has a market cap of 9.4B. Regarding current trading prices, BIOGY is priced at $11.00, while IPSEF trades at $113.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas IPSEF's P/E ratio is 18.07. In terms of profitability, BIOGY's ROE is +0.24%, compared to IPSEF's ROE of +0.12%. Regarding short-term risk, BIOGY is less volatile compared to IPSEF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check IPSEF's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, ESALF has a market cap of 8.5B. Regarding current trading prices, BIOGY is priced at $11.00, while ESALF trades at $30.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas ESALF's P/E ratio is 27.27. In terms of profitability, BIOGY's ROE is +0.24%, compared to ESALF's ROE of +0.05%. Regarding short-term risk, BIOGY is less volatile compared to ESALF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check ESALF's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, ESAIY has a market cap of 8.4B. Regarding current trading prices, BIOGY is priced at $11.00, while ESAIY trades at $7.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas ESAIY's P/E ratio is 27.41. In terms of profitability, BIOGY's ROE is +0.24%, compared to ESAIY's ROE of +0.05%. Regarding short-term risk, BIOGY is less volatile compared to ESAIY. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check ESAIY's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, SFOSF has a market cap of 6.9B. Regarding current trading prices, BIOGY is priced at $11.00, while SFOSF trades at $2.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas SFOSF's P/E ratio is 13.68. In terms of profitability, BIOGY's ROE is +0.24%, compared to SFOSF's ROE of +0.09%. Regarding short-term risk, BIOGY and SFOSF have similar daily volatility (0.00).Check SFOSF's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, GZPHF has a market cap of 6.2B. Regarding current trading prices, BIOGY is priced at $11.00, while GZPHF trades at $2.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas GZPHF's P/E ratio is 9.00. In terms of profitability, BIOGY's ROE is +0.24%, compared to GZPHF's ROE of +0.08%. Regarding short-term risk, BIOGY and GZPHF have similar daily volatility (0.00).Check GZPHF's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, LVZPF has a market cap of 6.1B. Regarding current trading prices, BIOGY is priced at $11.00, while LVZPF trades at $5.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas LVZPF's P/E ratio is 15.35. In terms of profitability, BIOGY's ROE is +0.24%, compared to LVZPF's ROE of +0.14%. Regarding short-term risk, BIOGY is less volatile compared to LVZPF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check LVZPF's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, HLBBF has a market cap of 5.3B. Regarding current trading prices, BIOGY is priced at $11.00, while HLBBF trades at $6.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas HLBBF's P/E ratio is 13.04. In terms of profitability, BIOGY's ROE is +0.24%, compared to HLBBF's ROE of +0.13%. Regarding short-term risk, BIOGY and HLBBF have similar daily volatility (0.00).Check HLBBF's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, HLUBF has a market cap of 4.8B. Regarding current trading prices, BIOGY is priced at $11.00, while HLUBF trades at $4.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas HLUBF's P/E ratio is 9.64. In terms of profitability, BIOGY's ROE is +0.24%, compared to HLUBF's ROE of +0.13%. Regarding short-term risk, BIOGY is less volatile compared to HLUBF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check HLUBF's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, DNPUF has a market cap of 4.5B. Regarding current trading prices, BIOGY is priced at $11.00, while DNPUF trades at $11.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas DNPUF's P/E ratio is 4.68. In terms of profitability, BIOGY's ROE is +0.24%, compared to DNPUF's ROE of +0.49%. Regarding short-term risk, BIOGY is less volatile compared to DNPUF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check DNPUF's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, SMDPY has a market cap of 4.5B. Regarding current trading prices, BIOGY is priced at $11.00, while SMDPY trades at $11.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas SMDPY's P/E ratio is 4.61. In terms of profitability, BIOGY's ROE is +0.24%, compared to SMDPY's ROE of +0.49%. Regarding short-term risk, BIOGY and SMDPY have similar daily volatility (0.00).Check SMDPY's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, SGFEF has a market cap of 4.4B. Regarding current trading prices, BIOGY is priced at $11.00, while SGFEF trades at $100.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas SGFEF's P/E ratio is 20.53. In terms of profitability, BIOGY's ROE is +0.24%, compared to SGFEF's ROE of +0.16%. Regarding short-term risk, BIOGY is less volatile compared to SGFEF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check SGFEF's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, HKMPY has a market cap of 4.1B. Regarding current trading prices, BIOGY is priced at $11.00, while HKMPY trades at $37.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas HKMPY's P/E ratio is 10.28. In terms of profitability, BIOGY's ROE is +0.24%, compared to HKMPY's ROE of +0.16%. Regarding short-term risk, BIOGY is less volatile compared to HKMPY. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check HKMPY's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, HKMPF has a market cap of 3.9B. Regarding current trading prices, BIOGY is priced at $11.00, while HKMPF trades at $18.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas HKMPF's P/E ratio is 10.00. In terms of profitability, BIOGY's ROE is +0.24%, compared to HKMPF's ROE of +0.16%. Regarding short-term risk, BIOGY is less volatile compared to HKMPF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check HKMPF's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, APNHF has a market cap of 3.9B. Regarding current trading prices, BIOGY is priced at $11.00, while APNHF trades at $8.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas APNHF's P/E ratio is -34.76. In terms of profitability, BIOGY's ROE is +0.24%, compared to APNHF's ROE of -0.02%. Regarding short-term risk, BIOGY is less volatile compared to APNHF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check APNHF's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, APNHY has a market cap of 3.6B. Regarding current trading prices, BIOGY is priced at $11.00, while APNHY trades at $8.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas APNHY's P/E ratio is -32.16. In terms of profitability, BIOGY's ROE is +0.24%, compared to APNHY's ROE of -0.02%. Regarding short-term risk, BIOGY is less volatile compared to APNHY. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check APNHY's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, LBTSF has a market cap of 3.3B. Regarding current trading prices, BIOGY is priced at $11.00, while LBTSF trades at $15.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas LBTSF's P/E ratio is 59.04. In terms of profitability, BIOGY's ROE is +0.24%, compared to LBTSF's ROE of +0.04%. Regarding short-term risk, BIOGY and LBTSF have similar daily volatility (0.00).Check LBTSF's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, CHSYF has a market cap of 3.3B. Regarding current trading prices, BIOGY is priced at $11.00, while CHSYF trades at $1.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas CHSYF's P/E ratio is 13.50. In terms of profitability, BIOGY's ROE is +0.24%, compared to CHSYF's ROE of +0.09%. Regarding short-term risk, BIOGY is less volatile compared to CHSYF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check CHSYF's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, HYPMY has a market cap of 3.3B. Regarding current trading prices, BIOGY is priced at $11.00, while HYPMY trades at $4.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas HYPMY's P/E ratio is 8.91. In terms of profitability, BIOGY's ROE is +0.24%, compared to HYPMY's ROE of +0.13%. Regarding short-term risk, BIOGY is less volatile compared to HYPMY. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check HYPMY's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, INVVY has a market cap of 3B. Regarding current trading prices, BIOGY is priced at $11.00, while INVVY trades at $21.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas INVVY's P/E ratio is -62.42. In terms of profitability, BIOGY's ROE is +0.24%, compared to INVVY's ROE of -0.42%. Regarding short-term risk, BIOGY and INVVY have similar daily volatility (0.00).Check INVVY's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, IZQVF has a market cap of 2.9B. Regarding current trading prices, BIOGY is priced at $11.00, while IZQVF trades at $20.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas IZQVF's P/E ratio is -56.68. In terms of profitability, BIOGY's ROE is +0.24%, compared to IZQVF's ROE of -0.99%. Regarding short-term risk, BIOGY and IZQVF have similar daily volatility (0.00).Check IZQVF's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, CURLF has a market cap of 2.5B. Regarding current trading prices, BIOGY is priced at $11.00, while CURLF trades at $3.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas CURLF's P/E ratio is -10.19. In terms of profitability, BIOGY's ROE is +0.24%, compared to CURLF's ROE of -0.29%. Regarding short-term risk, BIOGY is less volatile compared to CURLF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check CURLF's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, HMDCF has a market cap of 2.4B. Regarding current trading prices, BIOGY is priced at $11.00, while HMDCF trades at $2.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas HMDCF's P/E ratio is 5.32. In terms of profitability, BIOGY's ROE is +0.24%, compared to HMDCF's ROE of +0.41%. Regarding short-term risk, BIOGY is less volatile compared to HMDCF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check HMDCF's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, ULIHF has a market cap of 2.3B. Regarding current trading prices, BIOGY is priced at $11.00, while ULIHF trades at $1.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas ULIHF's P/E ratio is 7.44. In terms of profitability, BIOGY's ROE is +0.24%, compared to ULIHF's ROE of +0.13%. Regarding short-term risk, BIOGY is less volatile compared to ULIHF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check ULIHF's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, NPPNY has a market cap of 2.2B. Regarding current trading prices, BIOGY is priced at $11.00, while NPPNY trades at $8.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas NPPNY's P/E ratio is 11.01. In terms of profitability, BIOGY's ROE is +0.24%, compared to NPPNY's ROE of +0.12%. Regarding short-term risk, BIOGY is less volatile compared to NPPNY. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check NPPNY's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, DMPHF has a market cap of 2.1B. Regarding current trading prices, BIOGY is priced at $11.00, while DMPHF trades at $39.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas DMPHF's P/E ratio is 17.90. In terms of profitability, BIOGY's ROE is +0.24%, compared to DMPHF's ROE of +0.20%. Regarding short-term risk, BIOGY is less volatile compared to DMPHF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check DMPHF's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, NPNKF has a market cap of 2.1B. Regarding current trading prices, BIOGY is priced at $11.00, while NPNKF trades at $31.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas NPNKF's P/E ratio is 10.57. In terms of profitability, BIOGY's ROE is +0.24%, compared to NPNKF's ROE of +0.11%. Regarding short-term risk, BIOGY is less volatile compared to NPNKF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check NPNKF's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, HTSUF has a market cap of 2B. Regarding current trading prices, BIOGY is priced at $11.00, while HTSUF trades at $29.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas HTSUF's P/E ratio is 16.76. In terms of profitability, BIOGY's ROE is +0.24%, compared to HTSUF's ROE of +0.07%. Regarding short-term risk, BIOGY and HTSUF have similar daily volatility (0.00).Check HTSUF's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, ARSUF has a market cap of 1.9B. Regarding current trading prices, BIOGY is priced at $11.00, while ARSUF trades at $26.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas ARSUF's P/E ratio is 18.30. In terms of profitability, BIOGY's ROE is +0.24%, compared to ARSUF's ROE of +0.17%. Regarding short-term risk, BIOGY is less volatile compared to ARSUF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check ARSUF's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, DUTV has a market cap of 1.9B. Regarding current trading prices, BIOGY is priced at $11.00, while DUTV trades at $0.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas DUTV's P/E ratio is N/A. In terms of profitability, BIOGY's ROE is +0.24%, compared to DUTV's ROE of -0.04%. Regarding short-term risk, BIOGY is less volatile compared to DUTV. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check DUTV's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, GTBIF has a market cap of 1.8B. Regarding current trading prices, BIOGY is priced at $11.00, while GTBIF trades at $7.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas GTBIF's P/E ratio is 16.23. In terms of profitability, BIOGY's ROE is +0.24%, compared to GTBIF's ROE of +0.06%. Regarding short-term risk, BIOGY is less volatile compared to GTBIF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check GTBIF's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, TCNNF has a market cap of 1.8B. Regarding current trading prices, BIOGY is priced at $11.00, while TCNNF trades at $9.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas TCNNF's P/E ratio is -15.90. In terms of profitability, BIOGY's ROE is +0.24%, compared to TCNNF's ROE of -0.10%. Regarding short-term risk, BIOGY is less volatile compared to TCNNF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check TCNNF's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, TSMRF has a market cap of 1.7B. Regarding current trading prices, BIOGY is priced at $11.00, while TSMRF trades at $23.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas TSMRF's P/E ratio is 10.04. In terms of profitability, BIOGY's ROE is +0.24%, compared to TSMRF's ROE of +0.10%. Regarding short-term risk, BIOGY is less volatile compared to TSMRF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check TSMRF's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, SHPHF has a market cap of 1.7B. Regarding current trading prices, BIOGY is priced at $11.00, while SHPHF trades at $0.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas SHPHF's P/E ratio is -6.22. In terms of profitability, BIOGY's ROE is +0.24%, compared to SHPHF's ROE of +0.03%. Regarding short-term risk, BIOGY and SHPHF have similar daily volatility (0.00).Check SHPHF's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, MITPF has a market cap of 1.6B. Regarding current trading prices, BIOGY is priced at $11.00, while MITPF trades at $23.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas MITPF's P/E ratio is -10.81. In terms of profitability, BIOGY's ROE is +0.24%, compared to MITPF's ROE of +4.99%. Regarding short-term risk, BIOGY is less volatile compared to MITPF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check MITPF's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, KARBF has a market cap of 1.5B. Regarding current trading prices, BIOGY is priced at $11.00, while KARBF trades at $5.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas KARBF's P/E ratio is 262.50. In terms of profitability, BIOGY's ROE is +0.24%, compared to KARBF's ROE of N/A. Regarding short-term risk, BIOGY and KARBF have similar daily volatility (0.00).Check KARBF's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, CASBF has a market cap of 1.3B. Regarding current trading prices, BIOGY is priced at $11.00, while CASBF trades at $3.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas CASBF's P/E ratio is 193.00. In terms of profitability, BIOGY's ROE is +0.24%, compared to CASBF's ROE of -0.00%. Regarding short-term risk, BIOGY is less volatile compared to CASBF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check CASBF's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, SWGHF has a market cap of 1.3B. Regarding current trading prices, BIOGY is priced at $11.00, while SWGHF trades at $11.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas SWGHF's P/E ratio is 15.57. In terms of profitability, BIOGY's ROE is +0.24%, compared to SWGHF's ROE of +0.05%. Regarding short-term risk, BIOGY and SWGHF have similar daily volatility (0.00).Check SWGHF's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, LJUIF has a market cap of 1.2B. Regarding current trading prices, BIOGY is priced at $11.00, while LJUIF trades at $0.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas LJUIF's P/E ratio is 13.42. In terms of profitability, BIOGY's ROE is +0.24%, compared to LJUIF's ROE of +0.06%. Regarding short-term risk, BIOGY is less volatile compared to LJUIF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check LJUIF's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, CHIZF has a market cap of 1.1B. Regarding current trading prices, BIOGY is priced at $11.00, while CHIZF trades at $0.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas CHIZF's P/E ratio is -21.89. In terms of profitability, BIOGY's ROE is +0.24%, compared to CHIZF's ROE of -0.01%. Regarding short-term risk, BIOGY and CHIZF have similar daily volatility (0.00).Check CHIZF's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, KSPHF has a market cap of 1.1B. Regarding current trading prices, BIOGY is priced at $11.00, while KSPHF trades at $25.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas KSPHF's P/E ratio is 12.04. In terms of profitability, BIOGY's ROE is +0.24%, compared to KSPHF's ROE of +0.07%. Regarding short-term risk, BIOGY is less volatile compared to KSPHF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check KSPHF's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, GNMLF has a market cap of 1.1B. Regarding current trading prices, BIOGY is priced at $11.00, while GNMLF trades at $1.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas GNMLF's P/E ratio is 12.00. In terms of profitability, BIOGY's ROE is +0.24%, compared to GNMLF's ROE of +0.08%. Regarding short-term risk, BIOGY is less volatile compared to GNMLF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check GNMLF's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, KKPCF has a market cap of 984.6M. Regarding current trading prices, BIOGY is priced at $11.00, while KKPCF trades at $26.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas KKPCF's P/E ratio is 288.89. In terms of profitability, BIOGY's ROE is +0.24%, compared to KKPCF's ROE of -0.03%. Regarding short-term risk, BIOGY is less volatile compared to KKPCF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check KKPCF's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, EVOTF has a market cap of 930.6M. Regarding current trading prices, BIOGY is priced at $11.00, while EVOTF trades at $5.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas EVOTF's P/E ratio is -7.71. In terms of profitability, BIOGY's ROE is +0.24%, compared to EVOTF's ROE of -0.12%. Regarding short-term risk, BIOGY is less volatile compared to EVOTF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check EVOTF's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, TWAPF has a market cap of 828.5M. Regarding current trading prices, BIOGY is priced at $11.00, while TWAPF trades at $16.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas TWAPF's P/E ratio is 6.28. In terms of profitability, BIOGY's ROE is +0.24%, compared to TWAPF's ROE of +0.12%. Regarding short-term risk, BIOGY is less volatile compared to TWAPF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check TWAPF's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, CSWYF has a market cap of 758.4M. Regarding current trading prices, BIOGY is priced at $11.00, while CSWYF trades at $1.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas CSWYF's P/E ratio is 4.78. In terms of profitability, BIOGY's ROE is +0.24%, compared to CSWYF's ROE of +0.12%. Regarding short-term risk, BIOGY is less volatile compared to CSWYF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check CSWYF's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, GLASF has a market cap of 713.9M. Regarding current trading prices, BIOGY is priced at $11.00, while GLASF trades at $9.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas GLASF's P/E ratio is -16.76. In terms of profitability, BIOGY's ROE is +0.24%, compared to GLASF's ROE of -0.23%. Regarding short-term risk, BIOGY is less volatile compared to GLASF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check GLASF's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, TRXPF has a market cap of 690.7M. Regarding current trading prices, BIOGY is priced at $11.00, while TRXPF trades at $24.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas TRXPF's P/E ratio is 25.86. In terms of profitability, BIOGY's ROE is +0.24%, compared to TRXPF's ROE of +0.03%. Regarding short-term risk, BIOGY and TRXPF have similar daily volatility (0.00).Check TRXPF's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, SHEZF has a market cap of 689M. Regarding current trading prices, BIOGY is priced at $11.00, while SHEZF trades at $0.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas SHEZF's P/E ratio is -23.48. In terms of profitability, BIOGY's ROE is +0.24%, compared to SHEZF's ROE of +0.03%. Regarding short-term risk, BIOGY is less volatile compared to SHEZF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check SHEZF's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, YIHCF has a market cap of 643.1M. Regarding current trading prices, BIOGY is priced at $11.00, while YIHCF trades at $0.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas YIHCF's P/E ratio is -5.00. In terms of profitability, BIOGY's ROE is +0.24%, compared to YIHCF's ROE of +0.06%. Regarding short-term risk, BIOGY and YIHCF have similar daily volatility (0.00).Check YIHCF's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, AIHLF has a market cap of 624.3M. Regarding current trading prices, BIOGY is priced at $11.00, while AIHLF trades at $3.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas AIHLF's P/E ratio is 10.94. In terms of profitability, BIOGY's ROE is +0.24%, compared to AIHLF's ROE of +0.15%. Regarding short-term risk, BIOGY and AIHLF have similar daily volatility (0.00).Check AIHLF's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, TRSSF has a market cap of 601.9M. Regarding current trading prices, BIOGY is priced at $11.00, while TRSSF trades at $1.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas TRSSF's P/E ratio is -1.32. In terms of profitability, BIOGY's ROE is +0.24%, compared to TRSSF's ROE of -0.68%. Regarding short-term risk, BIOGY is less volatile compared to TRSSF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check TRSSF's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, AGYTF has a market cap of 554.6M. Regarding current trading prices, BIOGY is priced at $11.00, while AGYTF trades at $0.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas AGYTF's P/E ratio is -11.00. In terms of profitability, BIOGY's ROE is +0.24%, compared to AGYTF's ROE of +2.84%. Regarding short-term risk, BIOGY and AGYTF have similar daily volatility (0.00).Check AGYTF's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, PKBFF has a market cap of 544.7M. Regarding current trading prices, BIOGY is priced at $11.00, while PKBFF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas PKBFF's P/E ratio is N/A. In terms of profitability, BIOGY's ROE is +0.24%, compared to PKBFF's ROE of +7.96%. Regarding short-term risk, BIOGY and PKBFF have similar daily volatility (0.00).Check PKBFF's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, KHTRF has a market cap of 529.6M. Regarding current trading prices, BIOGY is priced at $11.00, while KHTRF trades at $5.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas KHTRF's P/E ratio is -135.05. In terms of profitability, BIOGY's ROE is +0.24%, compared to KHTRF's ROE of -0.01%. Regarding short-term risk, BIOGY is less volatile compared to KHTRF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check KHTRF's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, CCHWF has a market cap of 521.3M. Regarding current trading prices, BIOGY is priced at $11.00, while CCHWF trades at $0.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas CCHWF's P/E ratio is -1.12. In terms of profitability, BIOGY's ROE is +0.24%, compared to CCHWF's ROE of +0.42%. Regarding short-term risk, BIOGY is less volatile compared to CCHWF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check CCHWF's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, BOIRF has a market cap of 520.9M. Regarding current trading prices, BIOGY is priced at $11.00, while BOIRF trades at $30.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas BOIRF's P/E ratio is 22.73. In terms of profitability, BIOGY's ROE is +0.24%, compared to BOIRF's ROE of +0.05%. Regarding short-term risk, BIOGY and BOIRF have similar daily volatility (0.00).Check BOIRF's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, VRNOF has a market cap of 470.4M. Regarding current trading prices, BIOGY is priced at $11.00, while VRNOF trades at $1.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas VRNOF's P/E ratio is -1.31. In terms of profitability, BIOGY's ROE is +0.24%, compared to VRNOF's ROE of -0.31%. Regarding short-term risk, BIOGY is less volatile compared to VRNOF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check VRNOF's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, PEXXF has a market cap of 463.1M. Regarding current trading prices, BIOGY is priced at $11.00, while PEXXF trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas PEXXF's P/E ratio is 9.00. In terms of profitability, BIOGY's ROE is +0.24%, compared to PEXXF's ROE of N/A. Regarding short-term risk, BIOGY and PEXXF have similar daily volatility (0.00).Check PEXXF's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, HUMDF has a market cap of 430.9M. Regarding current trading prices, BIOGY is priced at $11.00, while HUMDF trades at $0.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas HUMDF's P/E ratio is 2.70. In terms of profitability, BIOGY's ROE is +0.24%, compared to HUMDF's ROE of +1.07%. Regarding short-term risk, BIOGY is less volatile compared to HUMDF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check HUMDF's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, NIKA has a market cap of 421.1M. Regarding current trading prices, BIOGY is priced at $11.00, while NIKA trades at $0.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas NIKA's P/E ratio is N/A. In terms of profitability, BIOGY's ROE is +0.24%, compared to NIKA's ROE of +0.29%. Regarding short-term risk, BIOGY is less volatile compared to NIKA. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check NIKA's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, SWDCF has a market cap of 399.6M. Regarding current trading prices, BIOGY is priced at $11.00, while SWDCF trades at $2.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas SWDCF's P/E ratio is 83.33. In terms of profitability, BIOGY's ROE is +0.24%, compared to SWDCF's ROE of +0.01%. Regarding short-term risk, BIOGY is less volatile compared to SWDCF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check SWDCF's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, ELTP has a market cap of 372.6M. Regarding current trading prices, BIOGY is priced at $11.00, while ELTP trades at $0.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas ELTP's P/E ratio is 8.65. In terms of profitability, BIOGY's ROE is +0.24%, compared to ELTP's ROE of +0.71%. Regarding short-term risk, BIOGY is less volatile compared to ELTP. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check ELTP's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, CRLBF has a market cap of 352M. Regarding current trading prices, BIOGY is priced at $11.00, while CRLBF trades at $1.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas CRLBF's P/E ratio is -2.70. In terms of profitability, BIOGY's ROE is +0.24%, compared to CRLBF's ROE of -0.33%. Regarding short-term risk, BIOGY is less volatile compared to CRLBF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check CRLBF's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, CPHRF has a market cap of 333.6M. Regarding current trading prices, BIOGY is priced at $11.00, while CPHRF trades at $13.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas CPHRF's P/E ratio is 12.57. In terms of profitability, BIOGY's ROE is +0.24%, compared to CPHRF's ROE of +0.24%. Regarding short-term risk, BIOGY is less volatile compared to CPHRF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check CPHRF's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, BHCCF has a market cap of 225.1M. Regarding current trading prices, BIOGY is priced at $11.00, while BHCCF trades at $0.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas BHCCF's P/E ratio is -4.57. In terms of profitability, BIOGY's ROE is +0.24%, compared to BHCCF's ROE of +0.29%. Regarding short-term risk, BIOGY is less volatile compared to BHCCF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check BHCCF's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, PLNHF has a market cap of 202M. Regarding current trading prices, BIOGY is priced at $11.00, while PLNHF trades at $0.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas PLNHF's P/E ratio is -3.50. In terms of profitability, BIOGY's ROE is +0.24%, compared to PLNHF's ROE of +659479.06%. Regarding short-term risk, BIOGY is less volatile compared to PLNHF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check PLNHF's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, PHCUF has a market cap of 188.1M. Regarding current trading prices, BIOGY is priced at $11.00, while PHCUF trades at $7.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas PHCUF's P/E ratio is -707.00. In terms of profitability, BIOGY's ROE is +0.24%, compared to PHCUF's ROE of -0.00%. Regarding short-term risk, BIOGY is less volatile compared to PHCUF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check PHCUF's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, SHIEF has a market cap of 179.4M. Regarding current trading prices, BIOGY is priced at $11.00, while SHIEF trades at $0.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas SHIEF's P/E ratio is -8.39. In terms of profitability, BIOGY's ROE is +0.24%, compared to SHIEF's ROE of +1.01%. Regarding short-term risk, BIOGY is less volatile compared to SHIEF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check SHIEF's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, CBWTF has a market cap of 139.2M. Regarding current trading prices, BIOGY is priced at $11.00, while CBWTF trades at $0.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas CBWTF's P/E ratio is 4.96. In terms of profitability, BIOGY's ROE is +0.24%, compared to CBWTF's ROE of +0.23%. Regarding short-term risk, BIOGY is less volatile compared to CBWTF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check CBWTF's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, COPHF has a market cap of 131.7M. Regarding current trading prices, BIOGY is priced at $11.00, while COPHF trades at $0.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas COPHF's P/E ratio is -0.02. In terms of profitability, BIOGY's ROE is +0.24%, compared to COPHF's ROE of -5.75%. Regarding short-term risk, BIOGY is less volatile compared to COPHF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check COPHF's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, LOVFF has a market cap of 126.4M. Regarding current trading prices, BIOGY is priced at $11.00, while LOVFF trades at $1.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas LOVFF's P/E ratio is 16.00. In terms of profitability, BIOGY's ROE is +0.24%, compared to LOVFF's ROE of +0.09%. Regarding short-term risk, BIOGY is less volatile compared to LOVFF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check LOVFF's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, NWPN has a market cap of 123.7M. Regarding current trading prices, BIOGY is priced at $11.00, while NWPN trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas NWPN's P/E ratio is -0.04. In terms of profitability, BIOGY's ROE is +0.24%, compared to NWPN's ROE of +0.13%. Regarding short-term risk, BIOGY is less volatile compared to NWPN. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check NWPN's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, BIOYF has a market cap of 122.2M. Regarding current trading prices, BIOGY is priced at $11.00, while BIOYF trades at $10.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas BIOYF's P/E ratio is 18.65. In terms of profitability, BIOGY's ROE is +0.24%, compared to BIOYF's ROE of +0.23%. Regarding short-term risk, BIOGY is less volatile compared to BIOYF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check BIOYF's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, LPCUF has a market cap of 112.1M. Regarding current trading prices, BIOGY is priced at $11.00, while LPCUF trades at $0.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas LPCUF's P/E ratio is 9.51. In terms of profitability, BIOGY's ROE is +0.24%, compared to LPCUF's ROE of +0.06%. Regarding short-term risk, BIOGY is less volatile compared to LPCUF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check LPCUF's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, CNVCF has a market cap of 109.2M. Regarding current trading prices, BIOGY is priced at $11.00, while CNVCF trades at $6.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas CNVCF's P/E ratio is -5.00. In terms of profitability, BIOGY's ROE is +0.24%, compared to CNVCF's ROE of +1.21%. Regarding short-term risk, BIOGY and CNVCF have similar daily volatility (0.00).Check CNVCF's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, HLTRF has a market cap of 107.6M. Regarding current trading prices, BIOGY is priced at $11.00, while HLTRF trades at $3.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas HLTRF's P/E ratio is -8.82. In terms of profitability, BIOGY's ROE is +0.24%, compared to HLTRF's ROE of -0.19%. Regarding short-term risk, BIOGY and HLTRF have similar daily volatility (0.00).Check HLTRF's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, AAWH has a market cap of 107.2M. Regarding current trading prices, BIOGY is priced at $11.00, while AAWH trades at $0.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas AAWH's P/E ratio is -0.91. In terms of profitability, BIOGY's ROE is +0.24%, compared to AAWH's ROE of -14.10%. Regarding short-term risk, BIOGY is less volatile compared to AAWH. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check AAWH's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, JUSHF has a market cap of 99.8M. Regarding current trading prices, BIOGY is priced at $11.00, while JUSHF trades at $0.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas JUSHF's P/E ratio is -1.43. In terms of profitability, BIOGY's ROE is +0.24%, compared to JUSHF's ROE of +0.76%. Regarding short-term risk, BIOGY is less volatile compared to JUSHF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check JUSHF's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, MEDXF has a market cap of 90.8M. Regarding current trading prices, BIOGY is priced at $11.00, while MEDXF trades at $2.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas MEDXF's P/E ratio is -140.50. In terms of profitability, BIOGY's ROE is +0.24%, compared to MEDXF's ROE of -0.01%. Regarding short-term risk, BIOGY is less volatile compared to MEDXF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check MEDXF's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, GRUSF has a market cap of 90M. Regarding current trading prices, BIOGY is priced at $11.00, while GRUSF trades at $0.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas GRUSF's P/E ratio is 36.00. In terms of profitability, BIOGY's ROE is +0.24%, compared to GRUSF's ROE of +0.00%. Regarding short-term risk, BIOGY is less volatile compared to GRUSF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check GRUSF's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, CWBHF has a market cap of 85.1M. Regarding current trading prices, BIOGY is priced at $11.00, while CWBHF trades at $0.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas CWBHF's P/E ratio is -2.79. In terms of profitability, BIOGY's ROE is +0.24%, compared to CWBHF's ROE of -2.75%. Regarding short-term risk, BIOGY is less volatile compared to CWBHF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check CWBHF's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, ABSCF has a market cap of 74.1M. Regarding current trading prices, BIOGY is priced at $11.00, while ABSCF trades at $1.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas ABSCF's P/E ratio is -6.22. In terms of profitability, BIOGY's ROE is +0.24%, compared to ABSCF's ROE of +0.33%. Regarding short-term risk, BIOGY and ABSCF have similar daily volatility (0.00).Check ABSCF's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, ORXOF has a market cap of 73.8M. Regarding current trading prices, BIOGY is priced at $11.00, while ORXOF trades at $2.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas ORXOF's P/E ratio is -1.62. In terms of profitability, BIOGY's ROE is +0.24%, compared to ORXOF's ROE of -2.28%. Regarding short-term risk, BIOGY is less volatile compared to ORXOF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check ORXOF's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, EOFBY has a market cap of 73.7M. Regarding current trading prices, BIOGY is priced at $11.00, while EOFBY trades at $0.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas EOFBY's P/E ratio is -7.67. In terms of profitability, BIOGY's ROE is +0.24%, compared to EOFBY's ROE of -0.77%. Regarding short-term risk, BIOGY and EOFBY have similar daily volatility (0.00).Check EOFBY's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, ORXOY has a market cap of 71.8M. Regarding current trading prices, BIOGY is priced at $11.00, while ORXOY trades at $2.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas ORXOY's P/E ratio is -1.64. In terms of profitability, BIOGY's ROE is +0.24%, compared to ORXOY's ROE of -2.28%. Regarding short-term risk, BIOGY and ORXOY have similar daily volatility (0.00).Check ORXOY's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, VEXTF has a market cap of 64M. Regarding current trading prices, BIOGY is priced at $11.00, while VEXTF trades at $0.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas VEXTF's P/E ratio is -3.69. In terms of profitability, BIOGY's ROE is +0.24%, compared to VEXTF's ROE of -0.27%. Regarding short-term risk, BIOGY is less volatile compared to VEXTF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check VEXTF's competition here

BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGY stands at 1.1B. In comparison, GDNSF has a market cap of 61M. Regarding current trading prices, BIOGY is priced at $11.00, while GDNSF trades at $0.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGY currently has a P/E ratio of 31.43, whereas GDNSF's P/E ratio is -2.66. In terms of profitability, BIOGY's ROE is +0.24%, compared to GDNSF's ROE of -0.69%. Regarding short-term risk, BIOGY and GDNSF have similar daily volatility (0.00).Check GDNSF's competition here